肝硬化上消化道出血患者预后因素分析

doi:10.3969/j.issn.1672-5069.2015.02.023

Abstract

Chen Chun, Wu Siguo, Yang ZhiJuan. Prognostic factors in patients with liver cirrhosis complicated by upper gastrointestinal bleeding[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 300-301.

[1] 钟志任,叶锋明.58例肝硬化上消化道出血病因分析.成都医学院学报,2012,7（11）：259.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[3] 李建生,张明礼.2007年美国肝硬化食管静脉曲张和出血防治指南. 胃肠病学和肝病学杂志,2008,17（2）:85-92.
[4] Mc cormack TT,Sims J,Eyre-brook I,et a1. Gastric lesions in portal hypertension：inflammatory gastritis or congestive gastroathy. Gut,1985,26（11）：1226.
[5] Manns MP,Czaja AJ,Gorham JD,et al. Diagnosis and management of autoimmune hepatitis. Hepatology,2010,51:2193-2213.
[6] 中华医学会消化内镜学分会. 食管胃静脉曲张内镜下诊断和治疗规范试行方案（2003年）. 中华消化内镜杂志,2004,21：149-151.
[7] 令狐恩.消化道静脉曲张及出血的内镜诊断和治疗规范试行方案（2009）. 中华消化内镜杂志,2010,27（7）：1-4.
[8] 周永兴. 现代肝硬化诊断治疗学. 人民军医出版社,2006:236-239.
[9] 邱德凯. 门脉高压性胃肠病研究. 国外医学消化疾病分册,2007,17（1）：17-20.
[10] 吴梓苗,冯杰,张爱军. 肝硬化上消化道出血预后相关因素分析,中国急救复苏与灾害医学杂志,2010,5,637-646.
[11] 杨惠林. 肝硬化患者凝血指标的检测分析. 齐齐哈尔医学院院报,2012,33（9）：1189.
[12] Koliscak L,Maynor L. Pharmacologic prophylaxis against venous thromboembolism in hospitalized patients with crrhosis and associated coagulopaties. Am J Health Syst Pharm,2012,69（8）:658-663.
[13] Bijak M,Saluk J,Ponczek MB,et al. Antithromhin effect of polyphenol-rich extracts from black chokeebeberry and grape seeds. Phytother Res,2012,10:4682.
[14] De Franchis R. Updating consensus in portal hypertension: report of the Baveno Ⅲ Consensus Workshop on definitions,methodology and therapeutic strategies in portal hypertension.J Hepatol,2000,33:846-852.
[15] Garcia-Tsao G. Current management of the complications of the cirrhosis and portal hypertension: variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology, 2001,120:726-748.

Prognostic factors in patients with liver cirrhosis complicated by upper gastrointestinal bleeding

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[3]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[6]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[7]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[8]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[11]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[12]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[13]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[14]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[15]	Qiu Jun, Wang Xueqing, Zhang Bo, et al. Percutaneous choledocholithotomy for the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2019, 22(5): 744-747.